RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ)

$1.52 -0.49 (-24.3781%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 75

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) News Sources

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

22-07-2026

yahoo.com

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

22-07-2026

yahoo.com

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

24-07-2026

yahoo.com

Radiopharm Theranostics Reports Business Update

31-07-2026

yahoo.com

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

14-09-2026

yahoo.com

RADX: RAD101 Topline & FY:26 Cash Flows

03-08-2026

yahoo.com

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

17-08-2026

yahoo.com

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

20-08-2026

yahoo.com

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

26-08-2026

yahoo.com

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

09-09-2026

yahoo.com

RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) Sentiment Trend

0 25 50 75 100 75 45 77 86 76 83 79 65 79 80 22-07-2026 24-07-2026 31-07-2026 14-09-2026 03-08-2026 17-08-2026 20-08-2026 26-08-2026 09-09-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) FAQs

toggle

What is the current price of RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ)?

The current price of RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) is $1.52.


toggle

RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) absolute price change since previous trading day?

The absolute price change of RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) since the previous trading day is $-0.49.


toggle

RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) percentage price change since previous trading day?

The percentage price change of RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) since the previous trading day is -24.3781%.


toggle

What is the most recent average sentiment score for RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ)?

The most recent average sentiment score for RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) is 75 out of 100.


toggle

What is the most recent average sentiment for RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ)?

The most recent sentiment for RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) is .


SEC-8K** Filing Available For RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.